Advanced Solid Malignancies: Clinical Trials

35 trials for Advanced Solid Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed. 35 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 135Completed 35
Phase 21Completed 1

Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
AZD5305, Itraconazole - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca162022-11-072024-06-18
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
Ceralasertib - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca122022-06-092024-08-02
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
YH002 - Advanced Solid Malignancies
Phase 1CompletedEucure (Beijing) Biopharma Co., Ltd152020-04-222022-07-22
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
AZD4635 - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca102019-07-042020-12-08
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
MEDI9447 (oleclumab) - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca62018-11-072019-07-08
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
AZD9150, Durvalumab - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca112018-01-302019-06-24
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
CT7001, Fulvestrant - Advanced Solid Malignancies
Phase 1 / Phase 2CompletedCarrick Therapeutics Limited1242017-11-142026-06-23
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
AZD4635, Durvalumab, Abiraterone Acetate - Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
Phase 1CompletedAstraZeneca3132016-06-172023-05-26
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment
MPT0E028 - Advanced Solid Malignancies
Phase 1CompletedTaipei Medical University232015-04-242019-04-11
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Fluzoparib - Advanced Solid Malignancies
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.792015-04-012019-06-17
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AZD2014 - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca282015-03-172024-12-17
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
AZD8835, AZD8835 in combination with fulvestrant - Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -
Phase 1CompletedAstraZeneca202014-11-012016-10-10
Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Gemcitabine HCl Oral Formulation - Advanced Solid Malignancies, Malignant Lymphomas
Phase 1CompletedInnoPharmax Inc.372013-04-012019-07-08
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
olaparib - Cancer, Advanced Solid Malignancies
Phase 1CompletedAstraZeneca232013-03-252018-01-16
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
AZD1208 - Advanced Solid Malignancies, Malignant Lymphoma
Phase 1CompletedAstraZeneca432012-07-012015-11-04
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
AZD6244 - Neoplasms,, Metastatic Cancer,
Phase 1CompletedAstraZeneca332012-06-012016-10-21
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
MEDI-573 - Cancer, Advanced Solid Malignancies
Phase 1CompletedAstraZeneca102011-07-012014-12-11
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
HM781-36B tablets - Advanced Solid Malignancies
Phase 1CompletedHanmi Pharmaceutical Company Limited202011-06-012013-05-23
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
MLN0128, paclitaxel, trastuzumab - Advanced Solid Malignancies, Hematologic Malignancies
Phase 1CompletedMillennium Pharmaceuticals, Inc.682011-02-282019-08-08
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
AZD4547 - Cancer, Advanced Solid Malignancies
Phase 1CompletedAstraZeneca402010-11-012016-06-29

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Neoplasms (12)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lymphoma (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Prostatic Neoplasms (1)

Broader conditions

Neoplasms (6)  ·  Neoplasms by Site (6)  ·  Hemic and Lymphatic Diseases (3)  ·  Neoplasms by Histologic Type (3)  ·  Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Genital Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lung Diseases (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Respiratory Tract Diseases (2)

Interventions

Fulvestrant (2)  ·  Irinotecan (2)  ·  durvalumab (2)  ·  olaparib (2)  ·  sapanisertib (2)  ·  vistusertib (2)  ·  (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (1)  ·  2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydropyrido(4,3-d)pyrimidin-5(6H)-one (1)  ·  3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1)  ·  4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1)  ·  AZD 6244 (1)  ·  AZD 8931 (1)  ·  AZD1208 (1)  ·  AZD4547 (1)  ·  AZD5305 (1)

Sponsors

AstraZeneca (20)  ·  Hanmi Pharmaceutical Company Limited (3)  ·  Millennium Pharmaceuticals, Inc. (2)  ·  Novartis Pharmaceuticals (2)  ·  Carrick Therapeutics Limited (1)  ·  Eucure (Beijing) Biopharma Co., Ltd (1)  ·  InnoPharmax Inc. (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Mayo Clinic (1)  ·  Regeneron Pharmaceuticals (1)  ·  Samyang Biopharmaceuticals Corporation (1)  ·  Taipei Medical University (1)

Countries

Japan (13)  ·  United States (7)  ·  South Korea (4)  ·  United Kingdom (4)  ·  China (3)  ·  Spain (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Moldova (1)  ·  Netherlands (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Charles Erlichman, M.D. (1)  ·  Chia-Chi Lin, MD (1)  ·  Dr. Udai Banerji (1)  ·  Edward Bradley, MD (1)  ·  Elisabeth Oelmann (1)  ·  Frank Neumann, MSD (1)  ·  Helen Lin (1)  ·  Hendrik-Tobias Arkenau, FRCP, PhD (1)  ·  Hideo Saka, MD, PhD (1)  ·  Hideo Saka, Medical Doctor (1)  ·  Ian Smith (1)  ·  Ian Smith, Medical Science Director (1)  ·  James Carmichael (1)

Results publications

PMID 22145984, PMID 22843211, PMID 23010851, PMID 23589215, PMID 25342141, PMID 26223436, PMID 28070720, PMID 28601972, PMID 32385714, PMID 32913286, PMID 36270753, PMID 37488191, PMID 38086998, PMID 41351730

NIH funding

2009 (2), 2008 (1), 2017 (1)